DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Refractory Shapes Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·14 Oct 2026, 11:27 am

Refractory Shapes

Refractory Shapes Limited has submitted a certificate to the stock exchanges in compliance with SEBI's Depositories and Participants Regulations, 2018. This regulatory filing is a standard procedural requirement for listed companies to update the market about their compliance status with the depository system.

This disclosure is primarily a routine corporate governance update. It confirms that the company is adhering to the regulatory framework governing its shareholding patterns and depository operations. For investors, this news is not a financial development but a confirmation of the company's continued compliance with listing norms.

Investors should treat this as a standard administrative update. There are no specific market-moving details provided in the filing. The stock's price action will likely remain unaffected by this routine regulatory submission.